the above titled paper examined the food and drug administration’s (fda’s) warning letters and notice of violations (nov) over a 10-year period. findings from this content analysis reinforced what has been the primary issue for prescription direct-to-consumer advertising (dtca) since its beginning, the fair balance of risk and benefit information. as opposed to another analysis in 2026 about th...

this commentary discusses pertinent issues from hyosun kim’s paper on online prescription drug promotion. the study is well-designed and the findings highlight some of the consequences of the food and drug administration’s (fda’s) decision to deregulate online advertising of prescription drugs. while kim’s findings confirm some of the early concerns, they also provide a perspective of implement...

despite increased availability of online promotional tools for prescription drug marketers, evidence on online prescription drug promotion is far from settled or conclusive. we highlight ways in which online prescription drug promotion is similar to conventional broadcast and print advertising and ways in which it differs. we also highlight five key areas for future research: branded drug websi...

Despite increased availability of online promotional tools for prescription drug marketers, evidence on online prescription drug promotion is far from settled or conclusive. We highlight ways in which online prescription drug promotion is similar to conventional broadcast and print advertising and ways in which it differs. We also highlight five key areas for future research: branded drug websi...

hyosun kim’s report “trouble spots in online direct to consumer prescription drug promotion: a content analysis of fda warning letters”aims to teach marketers how to avoid breaching current food and drug administration (fda) guidelines in their online drug promotion. while kim hopes to minimise the potential for online promotion to misinform consumers and the study is carefully conducted, teach...

kim’s overview of food and drug administration (fda) regulatory actions from 2005 to 2014 is a comprehensive analysis of the us regulatory experience with online direct-to-consumer advertising (dtca) of prescription medicines. this experience is of relevance internationally as online dtca reaches the english-speaking public globally, despite the illegality of dtca in most countries. the most co...

This commentary discusses pertinent issues from Hyosun Kim’s paper on online prescription drug promotion. The study is well-designed and the findings highlight some of the consequences of the Food and Drug Administration’s (FDA’s) decision to deregulate online advertising of prescription drugs. While Kim’s findings confirm some of the early concerns, they also provide a perspective of implement...

drug therapy is a complex and important process and because of the importance of drug interactions, especially in in-patients, accompanying problems and obstacles would exist as a result of concomitant use of drugs in these patients. for this purpose 3130 prescription order forms from bou-ali hospital were collected and all potential drug interactions presentwere extracted and evaluated in term...

background for the purpose of understanding the food and drug administration’s (fda’s) concerns regarding online promotion of prescription drugs advertised directly to consumers, this study examines notices of violations (novs) and warning letters issued by the fda to pharmaceutical manufacturers.   methods the fda’s warning letters and novs, which were issued to pharmaceutical companies over a...

0